ライフサイエンスコーパス: positron

1 re for systematic studies in this direction, positron acceleration is still at its infancy, with limi

2 variety of probe-based techniques (including positron annihilation lifetime spectroscopy (PALS), FTIR

3 Positron annihilation spectroscopy measurements confirm

4 With the aid of positron annihilation spectroscopy, this study, for the

5 efective SmNiO(3) is further analyzed by the positron annihilation spectroscopy.

6 We found that positron annihilations localize within a region of inter

7 high-intensity laser facilities can produce positron beams with high-current, femtosecond-scale dura

8 been also confirmed by molecular simulation, positron (e(+) ) annihilation lifetime spectroscopy, and

9 ional magnetic resonance imaging [fMRI], and positron electron tomography [PET]) to explain the funct

10 Positron electron tomography imaging using radiolabeled

11 trols (n = 12) using in vivo high-resolution positron emission tomographic imaging as well as postmor

12 measured at baseline using [18F]florbetapir positron emission tomographic imaging.

13 penumbra detection against full quantitative positron emission tomography ((15) O-PET), the gold stan

14 erved clinically by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET).

15 scaffold was studied as a template for (18)F-positron emission tomography ((18)F-PET) radiotracer dev

16 eceptor densities by using [(18)F]flumazenil positron emission tomography ([(18)F]FMZ-PET) and GABA c

17 ng been utilized in fluorodeoxyglucose-based positron emission tomography (FDG-PET) as a contrast mec

18 homa, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, afte

19 criteria with respect to fluorodeoxyglucose positron emission tomography (FDG-PET) response criteria

20 s underwent brain [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans.

21 canning on a simultaneous magnetic resonance-positron emission tomography (MR-PET) scanner with the s

22 ts who had a clinical evaluation and amyloid positron emission tomography (PET) (A), tau PET (T), and

23 elds, especially that of an important cancer positron emission tomography (PET) agent [(18)F]5-fluoro

24 e investigate the potential of (18)F-mFBG, a positron emission tomography (PET) analogue of the (123)

25 sing fMRI and brain glucose metabolism using positron emission tomography (PET) and (18)F-fluorodeoxy

26 urteen participants were scanned twice using positron emission tomography (PET) and [(11)C]carfentani

27 Positron emission tomography (PET) and [(11)C]UCB-J, a r

28 Fluorodeoxyglucose (FDG) positron emission tomography (PET) and cardiac magnetic

29 (11)C]rifampin (administered as a microdose) positron emission tomography (PET) and computed tomograp

30 ardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk.

31 ivo at the subfield level using simultaneous positron emission tomography (PET) and magnetic resonanc

32 Two longitudinal flortaucipir (FTP) positron emission tomography (PET) and magnetic resonanc

33 We combined [(11)C]PK11195 positron emission tomography (PET) and resting-state fun

34 Positron emission tomography (PET) and single-photon ima

35 Using positron emission tomography (PET) and the [(18)F]AV1451

36 Here, we provide a brief overview of positron emission tomography (PET) applications that cou

37 ce imaging (MRI) and (64)Cu-DOTA-trastuzumab positron emission tomography (PET) are used to estimate

38 y naltrexone measured with [(11)C]-LY2795050 positron emission tomography (PET) as a predictor of res

39 (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography (PET) at baseline and 6 mon

40 Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloi

41 (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can detect vascular i

42 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) combined with compute

43 Dosimetry models using preclinical positron emission tomography (PET) data are commonly emp

44 Amyloid positron emission tomography (PET) detects amyloid plaqu

45 approved cerebrospinal fluid or amyloid beta positron emission tomography (PET) diagnostic tests.

46 nt chemical scaffolds in pharmaceuticals and positron emission tomography (PET) diagnostics.

47 Positron emission tomography (PET) enables non-invasive

48 iffusion weighted imaging (DWI), and dynamic positron emission tomography (PET) for detection of meta

49 on emission computed tomography (SPECT), and positron emission tomography (PET) for ischemia diagnosi

50 measurement of receptor occupancy (RO) using positron emission tomography (PET) has been instrumental

51 ns between cerebral blood flow (CBF) and tau positron emission tomography (PET) images in independent

52 Herein, we report a (64)Cu positron emission tomography (PET) imaging agent that sh

53 We investigated whether positron emission tomography (PET) imaging allows identi

54 pecific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for

55 Moreover, by employing (64)Cu(2+), positron emission tomography (PET) imaging can be achiev

56 Towards this end, positron emission tomography (PET) imaging has emerged a

57 In vivo positron emission tomography (PET) imaging is a key moda

58 s (13-15) have been synthetized as potential positron emission tomography (PET) imaging ligands for m

59 Positron emission tomography (PET) imaging of the 18 kDa

60 Past acetylcholinesterase positron emission tomography (PET) imaging studies impli

61 We selected subjects from a previous positron emission tomography (PET) imaging study in epil

62 OPA) is a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging that is used

63 e levels of mGlu5 receptor availability with positron emission tomography (PET) imaging using the mGl

64 We here use in vivo positron emission tomography (PET) imaging, flow cytomet

65 (FTP) and (11)C-Pittsburgh compound-B (PiB) positron emission tomography (PET) imaging, we measured

66 acking of Abeta accumulation with [(11)C]PiB positron emission tomography (PET) imaging.

67 s radiopharmaceuticals and (86)Y tracers for positron emission tomography (PET) imaging.

68 luorides are widely used as radiotracers for positron emission tomography (PET) imaging.

69 vivo neuroinflammation using [(11)C]PK11195 positron emission tomography (PET) imaging.

70 ring probe [C-11]-(+)-PHNO was measured with positron emission tomography (PET) in 79 human subjects

71 Positron emission tomography (PET) is a diagnostic nucle

72 Radiomics using 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising approa

73 ed tomography (CT) compared with rubidium-82 positron emission tomography (PET) MBF estimates in a hi

74 Here, we create a non-invasive positron emission tomography (PET) methodology to track

75 Fluorine-18 flurpiridaz is a novel positron emission tomography (PET) myocardial perfusion

76 panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau pathologies in

77 Positron emission tomography (PET) plays key roles in dr

78 Coronary (18)F-sodium fluoride ((18)F-NaF) positron emission tomography (PET) provides an assessmen

79 Positron emission tomography (PET) provides quantitative

80 ated analogue of the previously reported CB2 positron emission tomography (PET) radioligand [(11)C]RS

81 relates minute-by-minute fluctuations of the positron emission tomography (PET) radioligand [11C]racl

82 [(11)C]carfentanil, a selective MOR agonist positron emission tomography (PET) radioligand, to inves

83 Positron emission tomography (PET) radioligands (radioac

84 scribes the radiolabeling of biotin with the positron emission tomography (PET) radionuclide carbon-1

85 ng cancer in vivo using a voltage-sensitive, positron emission tomography (PET) radiotracer known as

86 nd-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET) scan to guide consoli

87 with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the

88 All subjects underwent positron emission tomography (PET) scans with two differ

89 ive features for AD classification using tau positron emission tomography (PET) scans.

90 We examined (18) F-Flortaucipir (FTP)-positron emission tomography (PET) signal across 41 cort

91 logy and treatment of anxiety disorders, but positron emission tomography (PET) studies probing the t

92 In the current positron emission tomography (PET) study, we evaluated t

93 217 shows stronger correlations with the tau positron emission tomography (PET) tracer [(18)F]flortau

94 (18)F-PI-2620 is a positron emission tomography (PET) tracer with high bind

95 Positron emission tomography (PET) tracers that bind to

96 Positron emission tomography (PET) uses radiotracers to

97 Background Positron emission tomography (PET) using (18)F-sodium fl

98 ication-free participants with MDD underwent positron emission tomography (PET) using [(11)C]CUMI-101

99 tandard (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) viability.

100 dardized uptake value ratios (SUVRs) for tau positron emission tomography (PET) were compared among 1

101 MRI data and a subset (n = 90) with amyloid positron emission tomography (PET) were included.

102 [(11)C]NOP-1A and positron emission tomography (PET) were used to measure

103 riatal D(2) receptor binding (examined using positron emission tomography (PET) with (11)C-raclopride

104 e present study was to validate and optimize positron emission tomography (PET) with (11)C-vorozole f

105 lopment of radioligands for Y(1)R imaging by positron emission tomography (PET) with a special emphas

106 ment after several antibiotic therapiesand a positron emission tomography (PET) with hypercaptation s

107 ds that enable tracking brain amyloid or tau positron emission tomography (PET) with magnetic resonan

108 aromatase availability in the amygdala using positron emission tomography (PET) with the aromatase in

109 quantified DA D1 receptor availability using positron emission tomography (PET) with the radioligand

110 Here, we used positron emission tomography (PET) with the SV2A radioli

111 eta ((18)F-florbetapir or (18)F-florbetaben) positron emission tomography (PET), (18)F-flortaucipir P

112 respectively, were 0.91 and 0.92 for amyloid positron emission tomography (PET), 0.89 and 0.74 for (1

113 tion across the brain of older adults, using positron emission tomography (PET), and investigate how

114 (KOR) availability in the human brain using positron emission tomography (PET), before and after a c

115 mine release at rest using [(11)C]raclopride positron emission tomography (PET), functional connectiv

116 These techniques include positron emission tomography (PET), single-photon emissi

117 In positron emission tomography (PET), the finite range ove

118 (18)F]-fluoro-l-phenylalanine ([(18)F]-DOPA) positron emission tomography (PET), we compared dopamine

119 Using positron emission tomography (PET), we explored the asso

120 Using positron emission tomography (PET), we identified the do

121 hors sought to assess whether (18)F-fluoride positron emission tomography (PET)-computed tomography (

122 The relationship among positron emission tomography (PET)-derived extent of isc

123 On the basis of promising results of positron emission tomography (PET)-directed treatment ap

124 (18)F-PI-2620 is a next generation tau positron emission tomography (PET)-tracer that has demon

125 ides can be used for diagnostic imaging with positron emission tomography (PET).

126 florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET).

127 utoradiography, ex vivo biodistribution, and positron emission tomography (PET).

128 eased morbidity and mortality.(18)F-fluoride positron emission tomography (PET)/computed tomography (

129 rmine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (

130 (11)C-palmitate and (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (

131 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (

132 n this study, we sought to develop a bimodal positron emission tomography (PET)/fluorescent imaging a

133 All received an (18)F-DOPA positron emission tomography (PET)/magnetic resonance (M

134 Participants underwent Pittsburgh Compound B Positron Emission Tomography (PiB-PET) to assess fibrill

135 IC) for Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission Tomography - Computed Tomography (PET-

136 Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magnetic

137 athology (determined using neuropathology or positron emission tomography [PET]).

138 [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or

139 (18)F-fluorodeoxyglucose positron emission tomography allows for near-universal c

140 Using positron emission tomography and [(18)F]FPEB, we quantif

141 We used [(11)C]FLB 457 positron emission tomography and amphetamine to measure

142 ts for AD] cohort) underwent amyloid and tau positron emission tomography and answered several questi

143 mer Network) study group cohort with amyloid positron emission tomography and behavioral data.

144 on an APOE4 or APOE3 genetic background, by positron emission tomography and by gamma counter.

145 dictions of brain Abeta burden quantified by positron emission tomography and CSF concentrations of A

146 ent rest and vasodilator stress N-13 ammonia positron emission tomography and echocardiography.

147 elopmental advances in imaging tools such as positron emission tomography and magnetic resonance imag

148 Positron emission tomography and microsphere MBF measure

149 Furthermore, the recent advent of tau positron emission tomography and novel fluid-based bioma

150 ethods to measure myocardial blood flow with positron emission tomography and single-photon emission

151 raphy and nuclear imaging techniques such as positron emission tomography and white blood cell scinti

152 supported by cerebrospinal fluid or amyloid positron emission tomography biomarkers.

153 [(11)C]PBR28 Positron Emission Tomography brain imaging of the 18-kDa

154 ultaneous brain imaging with high-resolution positron emission tomography brain imaging.

155 Longitudinal amyloid small animal positron emission tomography demonstrates accelerated am

156 ars old underwent baseline [(11)C]raclopride positron emission tomography followed by open L-DOPA for

157 MRI and positron emission tomography have shown that neurodegene

158 Gating of positron emission tomography images has been shown to re

159 and [(67)Cu]Cu-MeCOSar-Tz revealed that the positron emission tomography images produced by the form

160 orophores to detect myeloid cells by in vivo positron emission tomography imaging and optical modalit

161 Noninvasive positron emission tomography imaging clearly reveals tha

162 protein in brain and lungs using functional positron emission tomography imaging in vivo.

163 Positron emission tomography imaging of the (64)Cu-label

164 tressors in conjunction with high resolution positron emission tomography imaging of the brain.

165 -HT modified NPs is confirmed by noninvasive positron emission tomography imaging studies.

166 on clinical profile, 18F-fluorodeoxyglucose-positron emission tomography imaging, cardiac magnetic r

167 ctreotide[Trp(2-CF(2)(18)F)] enables in vivo positron emission tomography imaging.

168 Bq(124)I-omburtamab was used for radioimmuno-positron emission tomography imaging.

169 oding and amyloid-beta accumulation with PiB-positron emission tomography imaging.

170 structural brain measures using [(11)C]UCB-J positron emission tomography in 18 patients with schizop

171 ctional magnetic resonance imaging and D2/3R positron emission tomography in 51 healthy volunteers, t

172 using the whole-brain analysis technique of positron emission tomography in male mice.

173 an papillomavirus-specific CD8(+) T cells by positron emission tomography in mice bearing human papil

174 We used positron emission tomography in rats to quantify regiona

175 CCR2 positron emission tomography is a promising new biomarke

176 been shown to be accurate when compared with positron emission tomography MBF measured in the same pa

177 ange between pyruvate and lactate but not by positron emission tomography measurements of HK-II-media

178 ve regional genetic effects of voxelwise FDG-positron emission tomography measures between 116 ROIs a

179 ence, photoacoustic, magnetic resonance, and positron emission tomography modalities.

180 0 mg/kg) or saline and then received in vivo positron emission tomography of striatal dopamine synthe

181 tomography, magnetic resonance imaging, and positron emission tomography provides important insights

182 nt model and human tissues, using a targeted positron emission tomography radiotracer ((64)Cu-DOTA-EC

183 synthesized and tested the performance of a positron emission tomography radiotracer ((68)Ga-DOTA [1

184 Positron emission tomography revealed that DCZ selective

185 ng procedure can be compressed into a single positron emission tomography scan session lasting less t

186 pressive disorder underwent one [(18)F]FEPPA positron emission tomography scan to measure PFC and ACC

187 d tomography (CT)/magnetic resonance imaging/positron emission tomography scans and at least 10% resp

188 is and activity on [(18)F]fluorodeoxyglucose positron emission tomography scans did not correlate wit

189 y control subjects completed high-resolution positron emission tomography scans with the novel FAAH r

190 In 4 DSP cases with 18F-fluorodeoxyglucose positron emission tomography scans, acute LV myocardial

191 Positron emission tomography studies have demonstrated l

192 Preclinical and human positron emission tomography studies have produced incon

193 We performed [(18) F]-fluorodopa positron emission tomography studies of 57 homozygous an

194 rospective [(18)F]-dihydroxyphenyl-L-alanine positron emission tomography study in antipsychotic naiv

195 We employed positron emission tomography to measure both dopamine re

196 of drug use or pre-existing traits, we used positron emission tomography to measure mGlu5 receptor a

197 Here we used positron emission tomography to show that MOR levels in

198 [(11)C]NOP-1A positron emission tomography was used to measure the bin

199 [(11)C]FLB 457 and positron emission tomography were used to measure D(2/3)

200 ingulate cortex, and prefrontal cortex using positron emission tomography with [(11)C]LY2795050.

201 abolism measured by (18)F-fluorodeoxyglucose positron emission tomography with and without improved s

202 F-fluorodeoxyglucose positron emission tomography with CT may noninvasively d

203 DFA metabolism and organ partitioning using positron emission tomography with oral and intravenous l

204 robabilistic reversal learning task and used positron emission tomography with the [(11)C]-(+)-PHNO a

205 hology measured in cerebrospinal fluid or by positron emission tomography(23).

206 1-M) after exposure, echocardiography, micro-positron emission tomography(u-PET), collagen quantifica

207 h lung immunopathology activity, measured by positron emission tomography, and tracked treatment resp

208 in vivo electrophysiology, calcium imaging, positron emission tomography, behavioral efficacy testin

209 years of clinical follow-up and with amyloid positron emission tomography, diffusion tensor imaging,

210 Patients undergoing cardiac stress positron emission tomography, echocardiogram, and renal

211 stribution volume (TSPO V(T)), measured with positron emission tomography, mainly reflects gliosis in

212 On baseline positron emission tomography, patients in the top Lp(a)

213 underwent structural MRI, (18)F-florbetapir positron emission tomography, pure tone audiometry and c

214 compounds described herein are applicable in positron emission tomography, single-photon emission com

215 ttern of annihilation photons detected using positron emission tomography, with respect to anatomical

216 TLG) measured with [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-

217 e accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FD

218 ty of multicancer blood testing coupled with positron emission tomography-computed tomography (PET-CT

219 vity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT

220 ted these functions in mice and humans using positron emission tomography-computed tomography (PET/CT

221 ctable levels of infection, as determined by positron emission tomography-computed tomography imaging

222 central location, adenocarcinoma, and higher positron emission tomography-computed tomography nodal s

223 was to evaluate the activity of FAP via FAPI-positron emission tomography-computed tomography scans i

224 FAPI-positron emission tomography-computed tomography scans o

225 FAPI-positron emission tomography-computed tomography scans r

226 d for 22 patients after whole-body CT during Positron Emission Tomography-CT.

227 rganoid and cell cultures as well as in vivo positron emission tomography-magnetic resonance imaging

228 ncreased BAT volume and activity measured by positron emission tomography-MRI.

229 chemosensitive to salvage therapy with: (1) positron emission tomography-positive disease or (2) bon

230 ally inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (<= 5 cm) N0

231 onary flow reserve (CFR) was determined from positron emission tomography.

232 ic resonance imaging, and fluorodeoxyglucose-positron emission tomography.

233 h glucose and palmitate tracer infusions and positron emission tomography.

234 al symptom severity in the past month before positron emission tomography.

235 ological evaluation and in vivo studies with positron emission tomography.

236 tery disease underwent serial (18)F-fluoride positron emission tomography.

237 users (8 females), using (11)C-nicotine and positron emission tomography.

238 althy males and measured brain activity with positron emission tomography.

239 (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-

240 by means of [(18)F]fluoro-2-deoxy-d-glucose Positron Emission Tomography/Computed Tomography ((18)F-

241 assess the role of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)FD

242 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FD

243 Myocardial perfusion imaging, including positron emission tomography/computed tomography (PET/CT

244 onance imaging, and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT

245 in quantitative (18)F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT

246 enously injected into the mice and imaged by positron emission tomography/computed tomography (PET/CT

247 ve total bone imaging (QTBI) using (18)F-NaF positron emission tomography/computed tomography (PET/CT

248 Patients who achieved a complete response by positron emission tomography/computed tomography at thei

249 nflammation using (18)F-2-fluorodeoxyglucose-positron emission tomography/computed tomography imaging

250 Dynamic positron emission tomography/computed tomography imaging

251 volume (1000 islets) could be visualized by positron emission tomography/computed tomography imaging

252 onium-89-oxine-labeled eosinophils by serial positron emission tomography/computed tomography imaging

253 Fluorodeoxyglucose positron emission tomography/computed tomography imaging

254 Patients underwent a 3-month post-CRT positron emission tomography/computed tomography scan an

255 on days 1 and 15, followed by an exploratory positron emission tomography/computed tomography scan.

256 ximab-AVD for 4 to 6 cycles based on interim positron emission tomography/computed tomography scannin

257 ts: The median (range) lung cavity volume on positron emission tomography/computed tomography scans w

258 TMTV was computed on baseline positron emission tomography/computed tomography using t

259 [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography was per

260 [F] fluoro-D-glucose positron emission tomography/computed tomography was use

261 d metabolic activity in the arterial wall on positron emission tomography/computed tomography, indica

262 low reserve (MFR) measured by cardiac (82)Rb-positron emission tomography/computed tomography.

263 dividuals underwent (18)F-fluorodeoxyglucose positron emission tomography/computed tomography; AmygA,

264 %, 80%, and 91% for (18)F-fluorodeoxyglucose positron emission tomography/CT and 60%, 100%, 100%, and

265 (18)F-Fluorodeoxyglucose positron emission tomography/CT and white blood cell sin

266 hybrid (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/magnetic resonance imaging

267 We used simultaneously acquired (11) C-PBR28 positron emission tomography/magnetic resonance imaging

268 reduced brain network activities detected by positron-emission computed tomography (PET).

269 We used flortaucipir positron-emission tomography (PET) and florbetapir PET t

270 We previously showed separation of the positron-emission tomography (PET) imaging tracer 3'-deo

271 lves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imag

272 -MRI) near-infrared spectroscopy (NIRS), and positron-emission tomography (PET).

273 ake were assessed by means of static 18F-FDG positron-emission tomography and computed tomography sca

274 eral carotid stenosis of >=50% underwent FDG-positron-emission tomography and NaF-positron-emission t

275 Positron-emission tomography can quantify these processe

276 ntified by Cerenkov energy transfer imaging, positron-emission tomography, and fluorescence imaging.

277 ent FDG-positron-emission tomography and NaF-positron-emission tomography.

278 d from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electro

279 nique multichelator construct labeled with a positron emitter (Cu-64, t(1/2) = 12.7 h) is coupled to

280 Carbon-11 ((11)C) is one of the most ideal positron emitters for labeling bioactive molecules for m

281 based on a pair of radioisotopes of copper: positron-emitting copper-64 ((64)Cu, t (1/2) = 12.7 h) a

282 SynTacs, when labeled with positron-emitting isotopes, can noninvasively image anti

283 dic pH of the tumour milieu, of pH-sensitive positron-emitting neutral copolymer micelles into polyca

284 in vivo, using a novel (68)Ga-labeled GLP-1r positron-emitting probe that supplied a quantitative in

285 d protocols to prepare agents labeled with a positron-emitting radionuclide (e.g., (18)F).

286 d of the native daratumumab labeled with the positron-emitting radionuclide zirconium 89 ((89)Zr) thr

287 utamate inhibitors of PSMA radiolabeled with positron-emitting radionuclides can be used for diagnost

288 to form stable complexes with either of the positron-emitting radionuclides gallium-68 (t(1/2) = 68

289 d from a location that is different from the positron-emitting source, resulting in image blurring.

290 ve source of high-quality ultra-relativistic positrons for laser-driven and particle-driven plasma wa

291 tems, such as those containing electrons and positrons, have also been studied within the NEO framewo

292 We have developed positron lymphography (PLG), a method to detect tumor-po

293 rsion of the gamma-ray photons into electron-positron pairs in a solid foil with high atomic number.

294 lf-lives, larger-scale production, and lower positron range than their (68)Ga-labeled counterparts.

295 Here, we report on the localization of positron range, and hence annihilation quanta, by strong

296 The measured electron and positron spectra are then used to reconstruct the spectr

297 omography (PET), the finite range over which positrons travel before annihilating with an electron pl

298 We used a beam of positrons with kinetic energies of [Formula: see text] e

299 the state-of-the-art eFRET GEVI Voltron into Positron, with kinetics and sensitivity equivalent to Vo

300 (55)Co is a promising isotope with high positron yield and a long half-life suitable for imaging